RBC Capital lowered the firm’s price target on Chemours to $28 from $30 and keeps a Sector Perform rating on the shares after its Q3 earnings miss. The analyst is citing a slower TiO2 recovery and softer APM demand, while TSS remains strong. The firm adds that it is now expecting a more modest recovery into 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CC:
